2021 Q1 Form 10-Q Financial Statement
#000143774921012213 Filed on May 14, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $2.150M | $2.000M |
| YoY Change | 7.5% | -23.37% |
| % of Gross Profit | ||
| Research & Development | $1.379M | $938.6K |
| YoY Change | 46.92% | -35.32% |
| % of Gross Profit | ||
| Depreciation & Amortization | $9.000K | $12.33K |
| YoY Change | -26.98% | -11.85% |
| % of Gross Profit | ||
| Operating Expenses | $3.531M | $2.937M |
| YoY Change | 20.22% | -27.74% |
| Operating Profit | -$3.531M | -$2.937M |
| YoY Change | 20.22% | -27.74% |
| Interest Expense | ||
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | -$7.000K | -$10.41K |
| YoY Change | -32.76% | 15.96% |
| Pretax Income | -$3.538M | -$2.947M |
| YoY Change | 20.04% | -27.64% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$3.538M | -$2.947M |
| YoY Change | 20.04% | -27.64% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.04 | |
| Diluted Earnings Per Share | -$38.23K | -$323.1K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 92.59M | 9.131M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $137.6M | $9.400M |
| YoY Change | 1363.83% | -52.04% |
| Cash & Equivalents | $137.6M | $9.351M |
| Short-Term Investments | ||
| Other Short-Term Assets | $77.24K | $134.5K |
| YoY Change | -42.58% | 381.16% |
| Inventory | ||
| Prepaid Expenses | $2.550M | $1.337M |
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $141.0M | $11.67M |
| YoY Change | 1108.79% | -43.85% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $15.84K | $29.73K |
| YoY Change | -46.74% | -38.33% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $16.47K | $17.22K |
| YoY Change | -4.36% | 0.0% |
| Total Long-Term Assets | $49.23K | $145.2K |
| YoY Change | -66.09% | -40.79% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $141.0M | $11.67M |
| Total Long-Term Assets | $49.23K | $145.2K |
| Total Assets | $141.1M | $11.81M |
| YoY Change | 1094.35% | -43.82% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $722.3K | $356.3K |
| YoY Change | 102.74% | -23.22% |
| Accrued Expenses | $151.2K | $52.47K |
| YoY Change | 188.06% | -29.89% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $1.379M | $908.0K |
| YoY Change | 51.9% | -39.11% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $0.00 | |
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $1.379M | $908.0K |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| Total Liabilities | $1.400M | $916.0K |
| YoY Change | 52.84% | -40.08% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$108.6M | -$97.02M |
| YoY Change | 11.97% | 19.92% |
| Common Stock | $251.2M | $107.2M |
| YoY Change | 134.28% | 7.57% |
| Preferred Stock | $671.0K | |
| YoY Change | -4.42% | |
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $139.7M | $10.90M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $141.1M | $11.81M |
| YoY Change | 1094.35% | -43.82% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$3.538M | -$2.947M |
| YoY Change | 20.04% | -27.64% |
| Depreciation, Depletion And Amortization | $9.000K | $12.33K |
| YoY Change | -26.98% | -11.85% |
| Cash From Operating Activities | -$4.408M | -$3.230M |
| YoY Change | 36.47% | 50.31% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | |
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | $0.00 |
| YoY Change | ||
| Cash From Investing Activities | $0.00 | |
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | $102.4M | |
| YoY Change | ||
| NET CHANGE | ||
| Cash From Operating Activities | -$4.408M | -3.230M |
| Cash From Investing Activities | $0.00 | |
| Cash From Financing Activities | $102.4M | |
| Net Change In Cash | $98.02M | -3.230M |
| YoY Change | -3134.68% | -135.16% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$4.408M | -$3.230M |
| Capital Expenditures | $0.00 | |
| Free Cash Flow | -$4.408M | |
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | atos |
Common Stock And Warrants Issued During Period Value New Issues
CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues
|
69668408 | |
| CY2020Q4 | atos |
Common Stock Warrant Lability
CommonStockWarrantLability
|
13003075 | |
| CY2021Q1 | atos |
Common Stock Warrant Lability
CommonStockWarrantLability
|
||
| CY2021Q1 | atos |
Common Stock Warrant Lability
CommonStockWarrantLability
|
||
| CY2021Q1 | atos |
Financial Exchange Fees Accrued Current
FinancialExchangeFeesAccruedCurrent
|
43500 | |
| CY2020Q4 | atos |
Financial Exchange Fees Accrued Current
FinancialExchangeFeesAccruedCurrent
|
||
| CY2021Q1 | atos |
Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
|
85089 | |
| CY2020Q1 | atos |
Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
|
-5316 | |
| CY2021Q1 | atos |
Issuance Of Common Stock And Warrants Issuance Costs
IssuanceOfCommonStockAndWarrantsIssuanceCosts
|
5493310 | |
| CY2021Q1 | atos |
Lessee Operating Lease Monthly Rent Payments
LesseeOperatingLeaseMonthlyRentPayments
|
750 | |
| CY2021Q1 | atos |
Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
|
185000000 | |
| CY2021Q1 | atos |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
69668408 | |
| CY2020Q1 | atos |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
||
| CY2021Q1 | atos |
Professional Services Current
ProfessionalServicesCurrent
|
172955 | |
| CY2020Q4 | atos |
Professional Services Current
ProfessionalServicesCurrent
|
128229 | |
| CY2021Q1 | atos |
Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
|
13003075 | |
| CY2020Q1 | atos |
Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
|
||
| CY2021Q1 | atos |
Research And Development Current
ResearchAndDevelopmentCurrent
|
1742363 | |
| CY2020Q4 | atos |
Research And Development Current
ResearchAndDevelopmentCurrent
|
1215834 | |
| CY2021Q1 | atos |
Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
|
720029 | |
| CY2020Q4 | atos |
Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
|
634940 | |
| CY2021Q1 | atos |
Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
|
32760302 | |
| CY2021Q1 | atos |
Working Capital
WorkingCapital
|
139652000 | |
| CY2021Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2021Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2021Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | |
| CY2021Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-03-31 | |
| CY2021Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2021Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
120824368 | |
| CY2021Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2021Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2021Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2021Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2021Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock, $0.18 par value | |
| CY2021Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
722281 | |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1588613 | |
| CY2021Q1 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
194497 | |
| CY2020Q4 | us-gaap |
Accrued Bonuses Current
AccruedBonusesCurrent
|
689635 | |
| CY2020Q4 | us-gaap |
Accrued Income Taxes
AccruedIncomeTaxes
|
0 | |
| CY2021Q1 | us-gaap |
Accrued Income Taxes
AccruedIncomeTaxes
|
0 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
151155 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
93367 | |
| CY2021Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
111231 | |
| CY2020Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
102918 | |
| CY2021Q1 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
184273 | |
| CY2020Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
171112 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
129887146 | |
| CY2021Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
139618860 | |
| CY2021Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
229498725 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
129887146 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
687752 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
639751 | |
| CY2021Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
639751 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
687752 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
32321523 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5569028 | |
| CY2021Q1 | us-gaap |
Assets
Assets
|
141080546 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
42839453 | |
| CY2021Q1 | us-gaap |
Assets Current
AssetsCurrent
|
141031313 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
42770175 | |
| CY2021Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
137573593 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9351141 | |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
39553671 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
39663671 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
12691136 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
137683593 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
9461141 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
98019922 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-3229995 | |
| CY2021Q1 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
137322778 | |
| CY2020Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
39345260 | |
| CY2021Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
27664205 | |
| CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2020Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.18 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.18 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
120824368 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
47548835 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
120824368 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
47548835 | |
| CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
21748374 | |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
8558778 | |
| CY2021Q1 | us-gaap |
Deposit Assets
DepositAssets
|
14218 | |
| CY2020Q4 | us-gaap |
Deposit Assets
DepositAssets
|
14218 | |
| CY2021Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
9255 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
12326 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.04 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.32 | |
| CY2021Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
490001 | |
| CY2020Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
963665 | |
| CY2021Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
8917 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
13375 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2152241 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1998389 | |
| CY2021Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3538069 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-2947420 | |
| CY2021Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
||
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-866332 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
63081 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
57788 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-25414 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-473664 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-433037 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-581173 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
108389 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
2949 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
|
-9434 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
736550 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
474776 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
8694 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
681 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
4500 | |
| CY2021Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
141080546 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
42839453 | |
| CY2021Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1379147 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
15671521 | |
| CY2021Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font: inherit;">1:</div> NATURE OF OPERATIONS</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> January 6, 2020, </div>we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">Atossa Therapeutics, Inc. (the “Company”) was incorporated on <div style="display: inline; font-style: italic; font: inherit;"> April 30, 2009, </div>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is currently focused on development of its pharmaceuticals for the treatment of the novel coronavirus ("COVID-<div style="display: inline; font-style: italic; font: inherit;">19"</div>), breast cancer and other breast conditions. The Company's fiscal year ends on <div style="display: inline; font-style: italic; font: inherit;"> December 31.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 21.45pt 0pt -18pt; text-align: justify; text-indent: 18pt;"><div style="display: inline; font-weight: bold;">Impact of the Novel Coronavirus </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -9pt;"> </div> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The continued spread of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is affecting the United States and global economies and <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the Company's operations and those of <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which the Company relies, including causing possible disruptions in the supply of the Company's Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">H201,</div> AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> and the conduct of current and future clinical trials. In addition, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic <div style="display: inline; font-style: italic; font: inherit;"> may </div>affect the operations of the U.S. FDA and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. The evolving COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic could also directly or indirectly impact the pace of enrollment in our clinical trials for at least the next several months and possibly longer as patients <div style="display: inline; font-style: italic; font: inherit;"> may </div>avoid or <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be able to travel to healthcare facilities and physicians' offices except for a health emergency. Such facilities and offices <div style="display: inline; font-style: italic; font: inherit;"> may </div>also be required to focus limited resources on non-clinical trial activities, including treatment of COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> patients, and <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be available, in whole or in part, for clinical trial activities related to the Company's products under development. We have <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any delay in drug supply for our ongoing and planned clinical studies, including studies of Endoxifen, AT-<div style="display: inline; font-style: italic; font: inherit;">301</div> and AT-<div style="display: inline; font-style: italic; font: inherit;">H201.</div> However, our Phase <div style="display: inline; font-style: italic; font: inherit;">2</div> clinical study of Endoxifen that was being conducted in Australia was enrolling slower than expected due in part to COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> restrictions. Also, although we have <div style="display: inline; font-style: italic; font: inherit;">not</div> yet received regulatory approval to start our MBD Endoxifen study in Sweden, the study site we plan to use in Sweden has been negatively impacted by COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> restrictions which must be lifted before we can begin our study there. We anticipate commencing the MBD Endoxifen study in Sweden soon after receiving all necessary regulatory approvals; subject to delays in enrollment due to COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> disruptions, the duration and severity of which we cannot predict. Additionally, while the potential economic impact brought by, and the duration of, the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is difficult to assess or predict, the impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic on the global financial markets <div style="display: inline; font-style: italic; font: inherit;"> may </div>reduce the Company's ability to access capital, which could negatively impact the Company's short-term and long-term liquidity. The ultimate impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic is highly uncertain and subject to change. We do <div style="display: inline; font-style: italic; font: inherit;">not</div> yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on the Company's liquidity, capital resources, operations, financial position and business and those of the <div style="display: inline; font-style: italic; font: inherit;">third</div> parties on which we rely. We will continue to monitor future enrollment in studies for potential restrictions on site visits, mammograms or the impositions of new restrictions on trials as a result of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic.</div> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </div> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In response to the Coronavirus pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on <div style="display: inline; font-style: italic; font: inherit;"> March 27, 2020. </div>On <div style="display: inline; font-style: italic; font: inherit;"> March 11, 2021, </div>President Biden signed an additional coronavirus relief package entitled the American Rescue Plan Act of <div style="display: inline; font-style: italic; font: inherit;">2021,</div> which included, among other things, provisions relating to stimulus payments to some Americans, extension of several CARES Act relief programs, expansion of the child tax credit, funding for vaccinations and other COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> related assistance programs. The CARES Act and the American Rescue Plan Act has <div style="display: inline; font-style: italic; font: inherit;">not</div> had a material impact on the Company; however, we will continue to examine the impacts that the CARES Act and the American Rescue Plan Act, as well as any future economic relief legislation, <div style="display: inline; font-style: italic; font: inherit;"> may </div>have on our business.</div></div> | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
102428710 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
||
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
||
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
||
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4408788 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3229995 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3538069 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2947420 | |
| CY2021Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-3538069 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-2947420 | |
| CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
3530728 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
2937009 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3530728 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2937009 | |
| CY2021Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
10700 | |
| CY2020Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
13300 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
8013 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
18053 | |
| CY2021Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
10700 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
14700 | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
8013 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
18053 | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.113 | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P210D | |
| CY2021Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
77239 | |
| CY2020Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
657662 | |
| CY2021Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
16468 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
17218 | |
| CY2021Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
7697 | |
| CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
4748 | |
| CY2021Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-7341 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-10411 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
15835 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
20632 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1378487 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
938620 | |
| CY2021Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
4291 | |
| CY2020Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
33279 | |
| CY2021Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
620 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
621 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
620 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
621 | |
| CY2021Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
1 | |
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
1 | |
| CY2021Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
2550452 | |
| CY2020Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
1813902 | |
| CY2021Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
554405 | |
| CY2020Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
417854 | |
| CY2021Q1 | us-gaap |
Prepaid Rent
PrepaidRent
|
18720 | |
| CY2020Q4 | us-gaap |
Prepaid Rent
PrepaidRent
|
4488 | |
| CY2021Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
102429000 | |
| CY2020Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | |
| CY2021Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
32760302 | |
| CY2020Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
110000 | |
| CY2021Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
110000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
110000 | |
| CY2021Q1 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
110000 | |
| CY2020Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
110000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-111898992 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-108627631 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-112165700 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
670000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
5108435 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
3.05 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
||
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
||
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
||
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
3865800 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7067436 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7067436 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.74 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.74 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
3865800 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
7067436 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
2.74 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
||
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
||
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
||
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
||
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
2943244 | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y32D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y131D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y131D | |
| CY2021Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
5238 | |
| CY2020Q1 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
4275 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
||
| CY2021Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
639751 | |
| CY2020Q1 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
687752 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13156005 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10896337 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
27167932 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
139701399 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" margin: 0pt 7.5pt; text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </div> <div style=" margin: 0pt; text-indent: 36pt; font-family: "Times New Roman", Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div> | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
92587168 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
9130984 |
